Objective:

To explore the association between specific baseline clinical variables (e.g., age, BMI) and short-term bodily pain improvement in fibromyalgia patients receiving paraprobiotic supplementation.

Key Findings:

• Bodily pain scores improved significantly at 2 months compared to baseline, indicating a positive response to treatment.
• Dyslipidemia was independently associated with lower bodily pain scores, suggesting a potential target for intervention.
• Time was significantly associated with bodily pain improvement (p = 0.0018), highlighting the importance of longitudinal assessment.

Interpretation:

The findings suggest that paraprobiotic supplementation may lead to improvements in bodily pain in fibromyalgia patients, particularly over a two-month period, with dyslipidemia being a notable factor in pain severity.

Limitations:

• Observational design limits causal inferences, as it cannot establish direct cause-and-effect relationships.
• Absence of a control group restricts the ability to compare outcomes against a non-treatment cohort.

Conclusion:

Further prospective controlled studies are needed to clarify symptom trajectories and the role of metabolic factors in fibromyalgia.